6 completed, 3 active not recruiting, 2 recruiting, 2 terminated. 15 Phase 3, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 15 | Completed 6, Active not recruiting 3, Recruiting 2, Terminated 2, Unknown 2 |
| Phase 2 | 6 | Recruiting 2, Unknown 2, Completed 1, Terminated 1 |
Follow MDS: new trials by email Literature Review of MDS trials Research Report on MDS
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation TSC-101, Control - AML, MDS | Phase 3 | Active not recruiting | TScan Therapeutics, Inc. | 310 | 2026-06-18 | 2026-10-05 |
| Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation Decitabine, Sorafenib (BAY-43-9006)，giritinib, Avastinib - AML, MDS | Phase 2 / Phase 3 | Recruiting | Ruijin Hospital | 126 | 2025-06-10 | 2025-05-18 |
| Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy Rabbit Anti-Human T-Lymphocyte Immunoglobulin (ATLG) - Leukemia, MDS | Phase 2 / Phase 3 | Recruiting | Peking University First Hospital | 24 | 2025-05-03 | 2026-08-05 |
| GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG Cyclophosphamide, ATG - Graft Vs Host Disease, Peripheral Blood Stem Cell Transplantation | Phase 3 | Active not recruiting | DKMS gemeinnützige GmbH | 640 | 2022-03-02 | 2026-08-27 |
| Hetrombopag for Low/Intermediate-1 Risk MDS With Thrombocytopenia Hetrombopag, Stanozolol Tablets - MDS | Phase 2 / Phase 3 | Unknown | Peking Union Medical College Hospital | 50 | 2021-10-01 | 2021-09-24 |
| Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS Azacitidine, all trans retinoic acid - AML, MDS | Phase 2 / Phase 3 | Unknown | The First Affiliated Hospital of Soochow University | 180 | 2021-05-01 | 2022-01-03 |
| A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies Cytarabine, Busulfan, Cyclophosphamide - Leukemia, MDS | Phase 3 | Active not recruiting | First Affiliated Hospital of Zhejiang University | 232 | 2020-09-01 | 2026-04-09 |
| APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS) APR-246 + azacitidine, Azacitidine - MDS | Phase 3 | Completed | Aprea Therapeutics | 154 | 2019-01-11 | 2025-03-18 |
| Haploidentical Donor vs mMUD in Hematological Malignancies Peripheral blood stem cells - AML, ALL | Phase 2 / Phase 3 | Completed | DKMS gemeinnützige GmbH | 98 | 2018-01-01 | 2024-08-07 |
| Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA rigosertib, Any approved or standard-of-care therapy, best supportive care (BSC) - Myelodysplastic Syndrome, MDS | Phase 3 | Terminated | Traws Pharma, Inc. | 372 | 2015-12-02 | 2022-09-26 |
| Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML Decitabine, HYDROXYUREA - MDS | Phase 3 | Completed | Groupe Francophone des Myelodysplasies | 170 | 2014-10-14 | 2021-11-19 |
| Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Darbepoetin alfa, Placebo - MDS | Phase 3 | Completed | Amgen | 147 | 2011-12-21 | 2017-12-19 |
| Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts ON 01910.Na - Myelodysplastic Syndromes, MDS | Phase 3 | Completed | Traws Pharma, Inc. | 299 | 2010-11-01 | 2020-06-30 |
| Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129) Azacitidine - Leukemia, AML | Phase 3 | Completed | M.D. Anderson Cancer Center | 187 | 2009-04-21 | 2020-01-14 |
| Stem Cell Transplantation for Hematological Malignancies Stem Cell Transplant, Busulfan, Cyclophosphamide - Leukemia, Lymphocytic, Acute, AML | Phase 2 / Phase 3 | Terminated | Masonic Cancer Center, University of Minnesota | 11 | 2000-06-07 | 2017-12-05 |
Myelodysplastic Syndromes (5) · Leukemia (3) · Anemia, Refractory, with Excess of Blasts (2) · Hematologic Neoplasms (2) · Leukemia, Myeloid, Acute (2) · Frailty (1) · Graft vs Host Disease (1) · Leukemia, Myelomonocytic, Chronic (1) · Lymphoma (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Hematologic Diseases (8) · Hemic and Lymphatic Diseases (8) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Bone Marrow Diseases (5) · Immune System Diseases (3) · Leukemia (3) · Leukemia, Myeloid (3) · Anemia (2) · Anemia, Refractory (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoproliferative Disorders (2) · Neoplasms by Site (2) · Pathologic Processes (2)
Azacitidine (3) · Cyclophosphamide (3) · Busulfan (2) · Decitabine (2) · ON 01910 (2) · Antilymphocyte Serum (1) · Bone Marrow Transplantation (1) · Cyclosporine (1) · Cytarabine (1) · Darbepoetin alfa (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1) · Hydroxyurea (1) · Melphalan (1) · Mycophenolic Acid (1)
DKMS gemeinnützige GmbH (2) · Traws Pharma, Inc. (2) · Amgen (1) · Aprea Therapeutics (1) · First Affiliated Hospital of Zhejiang University (1) · Groupe Francophone des Myelodysplasies (1) · M.D. Anderson Cancer Center (1) · Masonic Cancer Center, University of Minnesota (1) · Peking Union Medical College Hospital (1) · Peking University First Hospital (1) · Ruijin Hospital (1) · TScan Therapeutics, Inc. (1) · The First Affiliated Hospital of Soochow University (1)
United States (6) · China (5) · France (5) · Germany (5) · Belgium (3) · Italy (3) · Spain (3) · Austria (2) · Czechia (2) · Switzerland (2) · Australia (1) · Canada (1) · Croatia (1) · Estonia (1) · Greece (1)
Johannes Schetelig, Prof Dr med (2) · Steven M. Fruchtman, MD (2) · Bing Han, Docter (1) · David Sallman, MD, PhD (1) · Han Yue, Ph.D (1) · Margaret MacMillan, MD (1) · Richard E. Champlin, MD, BS (1) · Shrikanta Chattopadhyay, MD (1) · Yi Luo, MD (1)
PMID 26968357, PMID 27400247, PMID 33170934, PMID 33513373, PMID 36455187
2015 (2), 2009 (1)